239 related articles for article (PubMed ID: 28601958)
1. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression.
Ali FM; Kay R; Finlay AY; Piguet V; Kupfer J; Dalgard F; Salek MS
Qual Life Res; 2017 Nov; 26(11):3025-3034. PubMed ID: 28601958
[TBL] [Abstract][Full Text] [Related]
2. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
3. Mapping of Family Reported Outcome Measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values.
Shah R; Salek MS; Finlay AY; Kay R; Nixon SJ; Otwombe K; Ali FM; Ingram JR
Qual Life Res; 2024 Apr; 33(4):1107-1119. PubMed ID: 38402530
[TBL] [Abstract][Full Text] [Related]
4. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.
Vilsbøll AW; Kragh N; Hahn-Pedersen J; Jensen CE
Qual Life Res; 2020 Sep; 29(9):2529-2539. PubMed ID: 32297132
[TBL] [Abstract][Full Text] [Related]
5. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities.
Blome C; Beikert FC; Rustenbach SJ; Augustin M
Arch Dermatol Res; 2013 Apr; 305(3):197-204. PubMed ID: 23266843
[TBL] [Abstract][Full Text] [Related]
6. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
7. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
[TBL] [Abstract][Full Text] [Related]
8. Mapping of the Gastrointestinal Short Form Questionnaire (GSF-Q) into EQ-5D-3L and SF-6D in patients with gastroesophageal reflux disease.
Monroy M; Ruiz MA; Rejas J; Soto J
Health Qual Life Outcomes; 2018 Sep; 16(1):177. PubMed ID: 30200982
[TBL] [Abstract][Full Text] [Related]
9. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
Thompson NR; Lapin BR; Katzan IL
Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of health-related quality of life in psoriasis patients in Hungary].
Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
[TBL] [Abstract][Full Text] [Related]
11. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
12. Hand eczema and health-related quality of life; a comparison of EQ-5D and the Dermatology Life Quality Index (DLQI) in relation to the Hand Eczema Extent Score (HEES).
Lindberg M; Bingefors K; Meding B; Berg M
Contact Dermatitis; 2013 Sep; 69(3):138-43. PubMed ID: 23948032
[TBL] [Abstract][Full Text] [Related]
13. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
14. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
[TBL] [Abstract][Full Text] [Related]
15. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
Jia H; Zack MM; Moriarty DG; Fryback DG
Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
[TBL] [Abstract][Full Text] [Related]
16. General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys.
Stavem K; Augestad LA; Kristiansen IS; Rand K
Health Qual Life Outcomes; 2018 Oct; 16(1):204. PubMed ID: 30340499
[TBL] [Abstract][Full Text] [Related]
17. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
18. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
[TBL] [Abstract][Full Text] [Related]
19. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease.
Young MK; Ng SK; Mellick G; Scuffham PA
Qual Life Res; 2013 Jun; 22(5):1065-72. PubMed ID: 22782690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
